S. Kudoh

1.7k total citations
40 papers, 1.4k citations indexed

About

S. Kudoh is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, S. Kudoh has authored 40 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 33 papers in Oncology, 26 papers in Pulmonary and Respiratory Medicine and 15 papers in Molecular Biology. Recurrent topics in S. Kudoh's work include Lung Cancer Research Studies (25 papers), Lung Cancer Treatments and Mutations (21 papers) and Cancer therapeutics and mechanisms (15 papers). S. Kudoh is often cited by papers focused on Lung Cancer Research Studies (25 papers), Lung Cancer Treatments and Mutations (21 papers) and Cancer therapeutics and mechanisms (15 papers). S. Kudoh collaborates with scholars based in Japan, United Kingdom and United States. S. Kudoh's co-authors include Kazuhiko Nakagawa, N Masuda, Nobuhide Takifuji, M. Fukuoka, Kunihiko Matsui, Mitsutaka Takada, Masayuki Nishioka, Y Kusunoki, Tomohiro Tamura and Shunichi Negoro and has published in prestigious journals such as Journal of Clinical Oncology, JNCI Journal of the National Cancer Institute and British Journal of Cancer.

In The Last Decade

S. Kudoh

38 papers receiving 1.4k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
S. Kudoh Japan	14	1.1k	832	549	384	73	40	1.4k
M. Fukuoka Japan	16	1.1k 1.0×	787 0.9×	570 1.0×	334 0.9×	62 0.8×	62	1.4k
Nobuhide Takifuji Japan	15	1.2k 1.0×	988 1.2×	713 1.3×	350 0.9×	87 1.2×	42	1.7k
H Niitani Japan	17	1.4k 1.2×	862 1.0×	842 1.5×	174 0.5×	72 1.0×	61	1.8k
Y Kusunoki Japan	13	818 0.7×	834 1.0×	332 0.6×	119 0.3×	139 1.9×	27	1.2k
T. Hirashima Japan	19	896 0.8×	564 0.7×	660 1.2×	152 0.4×	30 0.4×	54	1.2k
A. Mathieu-Boué France	9	869 0.8×	522 0.6×	184 0.3×	131 0.3×	42 0.6×	14	1.1k
Adrian Langleben Canada	17	725 0.6×	316 0.4×	416 0.8×	167 0.4×	26 0.4×	55	1.1k
Stephen Lane United States	16	1.4k 1.2×	934 1.1×	344 0.6×	730 1.9×	7 0.1×	30	1.8k
Jeremy Kortmansky United States	13	1.0k 0.9×	434 0.5×	301 0.5×	307 0.8×	8 0.1×	49	1.4k
Griswold Dp United States	14	496 0.4×	338 0.4×	187 0.3×	102 0.3×	19 0.3×	19	885

Countries citing papers authored by S. Kudoh

Since Specialization

Citations

This map shows the geographic impact of S. Kudoh's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by S. Kudoh with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites S. Kudoh more than expected).

Fields of papers citing papers by S. Kudoh

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by S. Kudoh. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by S. Kudoh. The network helps show where S. Kudoh may publish in the future.

Co-authorship network of co-authors of S. Kudoh

This figure shows the co-authorship network connecting the top 25 collaborators of S. Kudoh. A scholar is included among the top collaborators of S. Kudoh based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with S. Kudoh. S. Kudoh is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Kogure, Yoshihito, Masahiko Ando, Hideo Saka, et al.. (2013). Histology and Smoking Status Predict Survival of Patients with Advanced Non–Small-Cell Lung Cancer: Results of West Japan Oncology Group (WJOG) Study 3906L. Journal of Thoracic Oncology. 8(6). 753–758. 37 indexed citations

Tada, Takuhito, et al.. (2010). Limited-stage small cell lung cancer: local failure after concurrent chemoradiotherapy with use of accelerated hyperfractionation. Japanese Journal of Radiology. 28(1). 43–47. 2 indexed citations

Takeda, Kazuhisa, Shunichi Negoro, Masahiro Tanaka, et al.. (2010). A Phase II Study of Cisplatin and Irinotecan As Induction Chemotherapy Followed by Concomitant Thoracic Radiotherapy with Weekly Low-dose Irinotecan in Unresectable, Stage III, Non-Small Cell Lung Cancer: JCOG 9706. Japanese Journal of Clinical Oncology. 41(1). 25–31. 7 indexed citations

Buyse, Marc, Pierre Squifflet, Silvy Laporte, et al.. (2008). Prediction of survival benefits from progression-free survival in patients with advanced non small cell lung cancer: Evidence from a pooled analysis of 2,838 patients randomized in 7 trials. Journal of Clinical Oncology. 26(15_suppl). 8019–8019. 22 indexed citations

Urata, Yoshiko, Takashi Seto, Isamu Okamoto, et al.. (2007). P3-151: EGFR mutation–based phase II multicenter trial of gefitinib in patients with advanced non–small cell lung cancer (NSCLC): Results of West Japan Thoracic Oncology Group trial (WJTOG0403). Journal of Thoracic Oncology. 2(8). S743–S744. 2 indexed citations

Laporte, Silvy, Marc Buyse, Noémie Baroux, et al.. (2007). B3-05: Meta-analysis comparing docetaxel and vinca-alkaloids in the first-line treatment of NSCLC. Comparison of results based on individual patient data, study report data, and published data. Journal of Thoracic Oncology. 2(8). S341–S342. 3 indexed citations

Okamoto, Hiroaki, Kenji Watanabe, Hiroshi Kunikane, et al.. (2007). Randomised phase III trial of carboplatin plus etoposide vs split doses of cisplatin plus etoposide in elderly or poor-risk patients with extensive disease small-cell lung cancer: JCOG 9702. British Journal of Cancer. 97(2). 162–169. 148 indexed citations

Nakagawa, Kazuhiko, Tomohiro Tamura, Shunichi Negoro, et al.. (2003). Phase I pharmacokinetic trial of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor gefitinib (‘Iressa’, ZD1839) in Japanese patients with solid malignant tumors. Annals of Oncology. 14(6). 922–930. 233 indexed citations

Fukuoka, Masahiro, Noriyuki Masuda, S. Kudoh, & Shunichi Negoro. (2000). Irinotecan in small-cell lung cancer--Japanese trials.. PubMed. 14(7 Suppl 5). 57–62. 5 indexed citations

10.

Tohda, Yuji, Takashi Iwanaga, Minoru Takada, et al.. (1999). Intrapleural Administration of Cisplatin and Etoposide to Treat Malignant Pleural Effusions in Patients with Non-Small Cell Lung Cancer. Chemotherapy. 45(3). 197–204. 27 indexed citations

11.

Takeda, Koji, Shunichi Negoro, S. Kudoh, et al.. (1999). Phase I/II study of weekly irinotecan and concurrent radiation therapy for locally advanced non-small cell lung cancer. British Journal of Cancer. 79(9-10). 1462–1467. 35 indexed citations

12.

Nishio, Kazuto, et al.. (1999). Combination effects of TAS-103, a novel dual topoisomerase I and II inhibitor, with other anticancer agents on human small cell lung cancer cells. Cancer Chemotherapy and Pharmacology. 43(5). 394–401. 22 indexed citations

13.

Yokose, Norio, Kíyoyuki Ogata, Hideto Tamura, et al.. (1998). Pulmonary toxicity after granulocyte colony-stimulating factor-combined chemotherapy for non-Hodgkin's lymphoma. British Journal of Cancer. 77(12). 2286–2290. 25 indexed citations

14.

Oshitani, Nobuhide, Takayuki Matsumoto, Yoshinori Moriyama, et al.. (1998). Drug-induced pneumonitis caused by sulfamethoxazole, trimethoprim during treatment of Pneumocystis carinii pneumonia in a patient with refractory ulcerative colitis. Journal of Gastroenterology. 33(4). 578–581. 8 indexed citations

15.

Masuda, N, M. Fukuoka, S. Kudoh, et al.. (1993). Phase I and pharmacologic study of irinotecan in combination with cisplatin for advanced lung cancer. British Journal of Cancer. 68(4). 777–782. 85 indexed citations

16.

Masuda, N, M. Fukuoka, Y Kusunoki, et al.. (1992). CPT-11: a new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer.. Journal of Clinical Oncology. 10(8). 1225–1229. 380 indexed citations

17.

Fukuoka, M., et al.. (1992). Mitomycin C, Vindesine, and Cisplatin in Advanced Non-Small-Cell Lung Cancer A Phase II Study. American Journal of Clinical Oncology. 15(1). 18–22. 7 indexed citations

18.

Fukuoka, M., N Masuda, Y Kusunoki, et al.. (1991). Phase I Study of Weekly Intravenous Infusions of CPT-11, a New Derivative of Camptothecin, in the Treatment of Advanced Non-Small-Cell Lung Cancer. JNCI Journal of the National Cancer Institute. 83(16). 1164–1168. 242 indexed citations

19.

Matsui, Kazuo, M. Fukuoka, Norikazu Masuda, et al.. (1991). [High-dose Tegafur (FT) for primary lung cancer: a phase I trial].. PubMed. 18(4). 593–9. 1 indexed citations

20.

Kudoh, S., Seung Ryu, Kuniaki Matsui, et al.. (1985). [Response and pharmacokinetics of cisplatin instilled into the pleural cavity].. PubMed. 12(11). 2161–5. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact